Thursday, February 5, 2009

GlaxoSmithKline and Genmab Seek European Marketing Authorisation of Arzerra in Advanced Stage Blood Cancer

GlaxoSmithKline (GSK) and Genmab A/S announced today the submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMEA) for Arzerra(TM)(ofatumumab) for the treatment of chronic lymphocytic leukaemia (CLL).

The details can be read here.

No comments: